Nasdaq:US$20.09 (-0.08) | HKEX:HK$31.60 (-0.45) | AIM:£3.24 (+0)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Group | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

  • The 15th Citi China Investor Conference on Thursday, November 5, 2020; and
  • The “China Summit Survey Results: Where is the “Bridge to Innovation” Headed?” Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

  • The Bank of America 2020 China Conference held from November 2 to 13, 2020;
  • The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020;
  • The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020;
  • The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and
  • The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at in the Shareholder Information section under “Events, Circulars & Forms.”


About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit:


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.



Investor Enquiries

Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786

Media Enquiries

Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
Zhou Yi, Brunswick +852 9783 6894 (Mobile)

Nominated Advisor

Freddy Crossley / Atholl Tweedie,
Panmure Gordon (UK) Limited
+44 (20) 7886 2500